---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-007532"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2024-06-07T23:59:59+00:00"
generated_at: "2026-06-01T05:41:40.539918+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dermata Therapeutics enters ATM equity facility for up to ~$1.16M

## Summary
- ATM Agreement with H.C. Wainwright for at-the-market issuance of common stock up to $1,157,761 aggregate market value.
- Commission rate 3.0% of gross sales price; expense reimbursement up to $70,000 plus periodic due diligence fees.
- Company has no obligation to sell; sales at prevailing market prices on Nasdaq under effective shelf registration statement.
- Offering terminates upon sale of all shares or earlier termination by either party.

## SEC filing metadata
- accession: 0001654954-24-007532
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2024-06-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495424007532/0001654954-24-007532-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495424007532/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-007532
- JSON: https://secwatch.observer/filing/0001654954-24-007532.json
- Plain text: https://secwatch.observer/filing/0001654954-24-007532.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.